Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications

References

• Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53(1):109–38
   Google Scholar
• Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322(7295): 1154–8
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life [The TTS­Fentanyl Comparative Trial Group]. J Pain Symptom Manage 1997;13(5):254–61
   PubMed Web of Science ®Google Scholar
• Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained­release oral morphine in patients with cancer and chronic non­cancer pain. Curr Med Res Opin 2004;20(9):1419–28
   PubMed Web of Science ®Google Scholar
• Gidwani S, Sathyan G, Sun T, Gupta SK. Pharmacokinetic investigation of dose proportionality across a new D­TRANS® fentanyl matrix delivery system (D­TRANS® fentanyl) dose range. Poster presentation. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M et al., editors. Pain practice. Blackwell Publishing; 2004. p. 288–9
   Google Scholar
• Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and in vitro evaluation of new drug­in­adhesive formulations of fentanyl transdermal patches. Acta Pharm 2004;54(4):301–17
   Google Scholar
• Andresen C, Cochien MS, Sun T, Gupta SK, Sathyan G. Evaluation of the skin sensitization potential of components of a new D­TRANS® fentanyl matrix delivery system (D­TRANS® fentanyl), exclusive of fentanyl (Placebo D­TRANS®). Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz­Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 288–9
   Google Scholar
• MLIC. Metropolitan height and weight tables. Stats Bull Met Life Insurance Company 1983;64:2–9
   Google Scholar
• Anderson LS, Grafelman DD, Carnes EJ, Sartwell CJ, Andaloro VJ, Lin PP. Development and validation of an exceptionally sensitive LC–MS/MS method to analyze fentanyl and naltrexone in human serum. AAPS PharmSci 2002;4(4):[abstract W5207]
   Google Scholar
• Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78(1):36–43
   Google Scholar
• Schuirmann DJ. A comparison of the two one­sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15(6):657–80
   PubMedGoogle Scholar
• Chow S, Liu J. Statistical methods for average bioavailability. In: Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992. p. 70–125
   Google Scholar
• FDA. Guidance for industry: statistical approaches to establishing bioequivalence. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001
   Google Scholar
• Gupta SK, Gidwani MS, Sun T, Sathyan G. Pharmacokinetic evaluation of a new D­TRANS® fentanyl matrix delivery system (D­TRANS® fentanyl) after single and repeated applications. Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz­Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 288–9
   Google Scholar
• CPMP. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). London: European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; 1999
   Google Scholar
• Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38(1):59–89
   PubMed Web of Science ®Google Scholar
• Sathyan G, Gidwani S, Sun T, Gupta SK. Evaluation of pharmacokinetic parameters in two skin types and age groups following a single application of a new D­TRANS® fentanyl matrix delivery system (D­TRANS® fentanyl). Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, Ruiz­Lopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 288­9
   Google Scholar
• Esteve M, Levron JC, Flaisler B, Schoefler P, Duvaldestin P, Chauvin M. Does aging modify pharmacokinetics of transdermal fentanyl? Anesthesiology 1991;75:A705
   PubMedGoogle Scholar